Novan Plans To Advance SB019 For Treatment Of COVID-19

(RTTNews) - Novan Inc. (NOVN) announced promising preclinical safety results with berdazimer sodium in a 14-day Good Laboratory Practices repeat dose intranasal toxicity study. It plans to advance SB019 for Treatment of COVID-19.

The preclinical study data indicated that intranasal administration of SB019 formulation containing berdazimer sodium is well-tolerated and safe. The company believes the promising conclusions from this Good Laboratory Practices study support advancement of the SB019 program toward in-human clinical development.

The company is continuing to progress the development of its potential anti-viral therapy against COVID-19, the disease caused by the SARS-CoV-2 virus.

The company remains focused on the next steps to submit an IND and initiates a phase 1 study in humans no later than the second quarter of 2022.